The morbidity caused by schistosomiasis has been controlled in China, Egypt and the
Philippines mainly by the widespread use of the safe and efficacious drug praziquantel …

Approximately 80% of the 200 million people infected with schistosomiasis inhabit sub-
Saharan Africa, and the annual mortality is estimated to be 280,000. Praziquantel is the drug …

Schistosomiasis is a major disease of public health importance in humans occurring in over
70 countries of the tropics and sub-tropics. In this chapter, the history of the control of …

The major antischistosomal drugs that have been or still are in use against infections with
schistosomes are considered here together with some compounds that have not been in …

No major changes have occurred during the past 20 years regarding the therapeutic tools
available to the clinician for the treatment of schistosomiasis. If anything, the two drugs …

Schistosomiasis, or bilharzias, is a neglected disease that remains a considerable public
health problem in tropical and subtropical regions. This parasitic disease is the most …

It has been often observed that the chemotherapeutic armamentarium against an important
disease such as schistosomiasis consists of just one drug, praziquantel. Thus, development …

Schistosomiasis is a chronic and debilitating disease that is caused by parasitic trematode
worms (schistosomes). It continues to threaten millions of people, particularly the rural poor …

A comprehensive 60-year review of antischistosomal drug discovery and development
research in the People's Republic of China (PR China) is presented. In the 1950s, three …

The current approach of morbidity control of schistosomiasis, a helminth disease of poverty
with considerable public health and socioeconomic impact, is based on preventive …